Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Scope of the Report
The report entitled “US Drug Eluting Sinus Stent (DESS) Market: Size, Trends & Forecasts (2016-2021)”, provides analysis of the US DESS market, with detailed analysis of market size and growth, penetration, market share and economic impact of the industry. The analysis includes the market by value (TAM), by volume and by utilization. The report also provides the analysis of the US sinus surgery market, including analysis of FESS market and BSD market.
Furthermore, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall US DESS market has also been forecasted for the years 2016-2021, taking into consideration the growth pattern of sinus surgery market, the growth drivers and the current and future trends.
Intersect is the only company manufacturing drug eluting sinus stents, but the competitive landscape of the market includes other indirect competitors, such as Medtronic, Entellus Medical and Acclarent (J&J), whose company profiling has been done in the report. In this segment of the report, business overview, financial overview and business strategies of the companies are provided.
Company Coverage
Intersect ENT
Medtronic (Xomed)
Entellus Medical
Acclarent (J&J)
Executive Summary
Sinuses are the hollow cavities located in the bones of the face and around the nose. There are four sinus cavities: frontal, maxillary, ethmoid, and sphenoid, each with different features. Under normal conditions, the secretion (mucous) flow through the nasal passages, but with the onset of sinusitis, the secretion gets blocked in the sinuses due to inflammation. Sinusitis disturbs the normal lifestyle of a person and sometimes become frustrating, as it affects the person’s breathing, sleeping and eating.
Sinusitis can be divided into Acute Sinusitis, Recurrent Acute Rhinosinusitis (RARS) and chronic Rhinosinusitis (CRS), on the basis of the duration of the episode of sinusitis and its severity. The treatment options for the sinusitis can be over-the-counter treatment, medical management and surgery. The OTC treatment includes decongestants, antihistamines, pain relievers and nasal irrigation. Medical management includes antibiotics and oral and nasal steroids. The sinus surgeries are mainly of two types: Functional Endoscopic Sinus Surgery (FESS) and Balloon Sinus Dilation (BSD).
Intersect, is the only company that has developed drug releasing bio-absorbable implants (drug eluting sinus stents- DESS) that enable targeted and sustained release of therapeutic agents, increasing the effectiveness of the sinus surgery.
The US DESS market is expected to increase at a significant growth rate during the forecasted period (2016-2021). The US DESS market is supported by various growth drivers, such as limitations of FESS treatment, benefits of DESS, increasing per capita healthcare expenditure, cost effectiveness of DESS, etc. Yet, the market faces certain challenges, such as, reimbursement issues, dependability on individual physician’s experience, limited trials after BSD, etc.
The report entitled “US Drug Eluting Sinus Stent (DESS) Market: Size, Trends & Forecasts (2016-2021)”, provides analysis of the US DESS market, with detailed analysis of market size and growth, penetration, market share and economic impact of the industry. The analysis includes the market by value (TAM), by volume and by utilization. The report also provides the analysis of the US sinus surgery market, including analysis of FESS market and BSD market.
Furthermore, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall US DESS market has also been forecasted for the years 2016-2021, taking into consideration the growth pattern of sinus surgery market, the growth drivers and the current and future trends.
Intersect is the only company manufacturing drug eluting sinus stents, but the competitive landscape of the market includes other indirect competitors, such as Medtronic, Entellus Medical and Acclarent (J&J), whose company profiling has been done in the report. In this segment of the report, business overview, financial overview and business strategies of the companies are provided.
Company Coverage
Intersect ENT
Medtronic (Xomed)
Entellus Medical
Acclarent (J&J)
Executive Summary
Sinuses are the hollow cavities located in the bones of the face and around the nose. There are four sinus cavities: frontal, maxillary, ethmoid, and sphenoid, each with different features. Under normal conditions, the secretion (mucous) flow through the nasal passages, but with the onset of sinusitis, the secretion gets blocked in the sinuses due to inflammation. Sinusitis disturbs the normal lifestyle of a person and sometimes become frustrating, as it affects the person’s breathing, sleeping and eating.
Sinusitis can be divided into Acute Sinusitis, Recurrent Acute Rhinosinusitis (RARS) and chronic Rhinosinusitis (CRS), on the basis of the duration of the episode of sinusitis and its severity. The treatment options for the sinusitis can be over-the-counter treatment, medical management and surgery. The OTC treatment includes decongestants, antihistamines, pain relievers and nasal irrigation. Medical management includes antibiotics and oral and nasal steroids. The sinus surgeries are mainly of two types: Functional Endoscopic Sinus Surgery (FESS) and Balloon Sinus Dilation (BSD).
Intersect, is the only company that has developed drug releasing bio-absorbable implants (drug eluting sinus stents- DESS) that enable targeted and sustained release of therapeutic agents, increasing the effectiveness of the sinus surgery.
The US DESS market is expected to increase at a significant growth rate during the forecasted period (2016-2021). The US DESS market is supported by various growth drivers, such as limitations of FESS treatment, benefits of DESS, increasing per capita healthcare expenditure, cost effectiveness of DESS, etc. Yet, the market faces certain challenges, such as, reimbursement issues, dependability on individual physician’s experience, limited trials after BSD, etc.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
